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In this issue of Immunity, Metkar et al. (2008) present evidence that granzyme A plays a role in inflammatory
signaling and that contrary to previous studies, it is incapable of inducing target cell death. The work
challenges us to reconsider the broader biological roles of all the granzymes.Together with the pore-forming protein
perforin, the family of granule-bound
serine proteases known as granzymes
forms an antiviral arsenal central to the
function of cytotoxic T lymphocyte
(CTL) and natural killer (NK) cells. The
prevailing view is that perforin facilitates
entry of granzymes into the cytoplasm
of a target cell, where they access their
substrates to trigger cell death (Vosko-
boinik et al., 2006). Humans and rodents
have three granzyme subfamilies en-
coded on distinct chromosomal loci: (1)
granzymes A and K have trypsin-like ac-
tivity; (2) granzyme M cleaves after un-
branched hydrophobic residues; and (3)
human granzymes B and H and rodent
granzymes B through G have chymotryp-
sin-like activity. Although there is no
doubt that granzyme B plays an impor-
tant role in inducing apoptosis, and it is
generally accepted that granzyme A can
trigger a distinct nonapoptotic form of
cell death, the cytotoxicity of other gran-
zymes is less certain. Over the years,
a number of other functions have been
suggested for granzymes, but few stud-ies have dealt with these topics, particu-
larly of late.
Although a molecular or cellular mecha-
nism is not comprehensively defined,
Metkar et al. (2008) now show that gran-
zyme A secreted by CTLs promotes the
release of IL-1b and other inflammatory
cytokines from antigen-presenting cells
such as primary mouse macrophages
in vitro. It is inferred from the data that
granzyme A enters activated monocytes
or macrophages to potently induce in-
flammatory cytokine release. Release
can be blocked with a caspase-1 inhibitor,
suggesting that the production of active
IL-1b does not result from direct process-
ing of pro-IL-1bby granzyme A. The in vivo
relevance of these findings is indicated by
the fact that mice deficient for granzyme A
are partially resistant to lipopolysaccha-
ride (LPS)-induced toxic shock, which is
known to be mediated by the release
of proinflammatory cytokines including
IL-1b. However, these results seem to be
confounded by the unexplained and
conflicting observations that granzyme
B-deficient mice are also resistant toImmunity 29, NLPS, whereas granzyme A and B doubly-
deficient mice are as sensitive as wild-
type. It is difficult to reconcile these
results, and we are also left to ponder
whether granzyme-mediated inflamma-
tion is perforin dependent.
A key question posed by Metkar et al.
(2008) is whether granzyme A plays any
significant role in target cell death. The
investigators use a variety of assays but
fail to reproduce the cytotoxic activity of
granzyme A other than at very high con-
centrations, thereby challenging the view
that cell-death induction is an important
and intrinsic function of this protease. To
put these findings into context, Hayes
et al. (1989) were the first to describe
synergy between granzymes and perforin
leading to apoptosis. Soon after, three dif-
ferent DNA-fragmenting activities within
rat CTL granules were identified as gran-
zyme A (fragmentin-1), granzyme B (frag-
mentin-2), and granzyme K (fragmentin-3)
(Shi et al., 1992). Further elegant studies
demonstrated that expression of perforin
in RBL-2H3 cells enables killing via necro-
sis, but that coexpression with granzymesovember 14, 2008 ª2008 Elsevier Inc. 665
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1995). Over the next decade, many labo-
ratories elaborated the mechanisms
leading to DNA fragmentation and death
induced by granzyme B, and the group
headed by J. Lieberman progressively
characterized a distinct caspase-inde-
pendent cell-death mechanism mediated
by human granzyme A.
In contrast to the studies of Shi et al.
(1992), the Lieberman group found that
vigorous single-stranded DNA nicking
rather than oligonucleosomal DNA frag-
mentation is the end-point of the gran-
zyme A death pathway. To explain this
discrepancy, Metkar et al. (2008) postu-
late that inadvertent granzyme B contam-
ination of granzyme A preparations
caused the observed DNA fragmenting
activity. In the Lieberman model, gran-
zyme A directly penetrates the mitochon-
drial matrix and disrupts the electron
transport chain through cleavage of com-
ponents of complex 1. How granzyme A
accesses the matrix is unknown, because
it lacks a mitochondrial targeting se-
quence. This important problem aside,
the induction of reactive oxygen species
production is proposed to cause translo-
cation of the SET complex into the
nucleus. Coincident cleavage of SET
proteins by granzyme A results in single-
stranded DNase activity that rapidly
causes cell death (see Martinvalet et al.,
2008).
How can we reconcile the findings of
Metkar et al. (2008) with the Lieberman
model (Martinvalet et al., 2008)? In sup-
port of Metkar et al. (2008), we have also
failed to confirm cell-death-inducing
activity of human granzyme A in vitro,
whereas that of mouse granzyme A was
at least an order of magnitude weaker
than human granzyme B (Kaiserman
et al., 2006). In vivo, granzyme A-deficient
mice have no defect of cytolysis or DNA
fragmentation, but the cytotoxic defect
for mice lacking both granzymes A and
B can be greater (depending on the target
cell) than for granzyme B-deficient mice.
Furthermore, expression of mouse gran-
zyme A in RBL cells increases the effi-
ciency of perforin-mediated death (Naka-
jima et al., 1995). These data indicate that
mouse granzyme A is cytotoxic and can
facilitate or amplify cell death caused by
other cytotoxins. Mice and humans pos-
sess a second ‘‘tryptase’’ (granzyme K),
so functional redundancy may mask a666 Immunity 29, November 14, 2008 ª2008defect in programmed cell death in gran-
zyme A-deficient mice. This possibility
will be excluded once mice deficient for
both granzymes are produced.
Significant species-specific differences
in the substrate specificity of granzymes
have recently been found (Kaiserman
et al., 2006), and thus it is likely that confu-
sion in the field has arisen through com-
parison of granzymes, perforins, and
cytotoxic lymphocytes of different spe-
cies, or through mixing components from
different species in the same in vitro ex-
periment. For instance, the Lieberman
group has largely used human granzyme
A in its biochemical studies, whereas
those working on biological functions have
used mouse granzyme A or mice lacking it.
An additional major caveat in vitro is that
nobody knows the effective concentration
at which granzymes or perforin are deliv-
ered to target cells at an authentic immu-
nological synapse, and this remains a
major impediment to determining how
much granzyme is needed to kill a given
target cell. Typically, low nanomolar con-
centrations of granzyme B and perforin
potently induce apoptosis, whereas cell
death caused by other granzymes (includ-
ing granzyme A) requires 500 to 2000 nM.
It may therefore be possible that applying
high concentrations of granzymes to cells
can result in nonphysiological death, and
that using micromolar concentrations of
protease on cell extracts may result in
cleavage of irrelevant substrates. On the
first point, Metkar et al. (2008) demon-
strate that addition of micromolar concen-
trations of active or inactive granzyme A
with perforin causes membrane damage
and necrosis, and we note that the Lie-
berman group routinely uses micromolar
granzyme A in cytotoxicity assays. On the
second point, caution should be applied
when searching for substrates in cell-free
systems, as illustrated by a recent pro-
teomics study that identified hundreds of
substrates when 200 nM granzyme B
was applied to cell extracts, but only
a handful when granzyme B was delivered
by a NK cell (Van Damme et al., 2008).
Such an approach will be necessary to
finally determine whether SET complex
components or inflammatory mediators
are true targets of granzyme A. Weighing
all of the above considerations, one way
to reconcile the Metkar et al. (2008) and
the Lieberman group findings is to suggest
that human granzyme A is not cytotoxicElsevier Inc.unless applied at excessive concen-
trations, whereas mouse granzyme A
possesses weak cell-death-promoting
activity. This does not rule out the target-
ing of SET complexes by human granzyme
A, but suggests that it is insufficient
to cause cell death. By contrast, both
human and mouse granzyme A seem
capable of initiating a proinflammatory
response.
The work of Metkar et al. (2008) forces
us to reassess the physiological relevance
of various proposed granzyme functions.
The fact that granzyme A-deficient mice
exhibit no apoptotic phenotype but are
somewhat resistant to LPS-induced toxic
shock points to the importance of gran-
zyme A in promoting proinflammatory
pathways preferentially over those that
lead to cell death. In our view, four criteria
make it clear that granzyme B is uniquely
and powerfully proapoptotic: (1) caspase-
like specificity, (2) potency at low nano-
molar concentrations, (3) classic apopto-
tic cell-death morphology, and (4) the
apoptosis-defective phenotype of gran-
zyme B-deficient mice. None of the other
granzymes fulfill these criteria, but re-
searchers proposing cytotoxic roles for
them might quite reasonably suggest
that they mobilize diverse cell-death
pathways to protect the host against vi-
ruses expressing a granzyme B inhibitor.
However, this can also be achieved by
directly targeting viral proteins. Indeed,
granzyme H directly cleaves two adenovi-
ral proteins: L4-100K, a capsid protein
that inhibits granzyme B-induced apopto-
sis, and a DNA-binding protein that is
vital for viral replication (Andrade et al.,
2007).
To summarize, re-evaluation of old and
new data leads us to propose that gran-
zyme B is the prime inducer of cell death,
whereas the other granzymes carry out
alternative functions including activation
of inflammatory pathways through pro-
IL-1b processing (Figure 1). Thus, gran-
zyme B is functionally equivalent to the
proapoptotic caspases, whereas other
granzymes mimic inflammatory cas-
pases. Both cell-death signaling and
pro-IL-1b processing occur in the cyto-
plasm, so a critical issue is whether the
proinflammatory actions of granzymes re-
quire perforin, as has been established for
granzyme B-induced apoptosis. The
study of Metkar et al. (2008) will no doubt
engender further interest in the
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cord with the prescient predictions made
by Kramer and Simon (1987) more than
twenty years ago.
Figure 1. Granzymes: Extrinsic Activators of Cell Death and Inflammation that Mimic
Intrinsic Caspase Pathways
Granzyme B, which like the proapoptotic caspases cleaves after specific Asp residues, is transferred from
a cytotoxic lymphocyte into the cytoplasm of a target or antigen-presenting cell to impose death in
response to virus infection or malignant transformation. Granzyme B (red dots) mediates this process in
a perforin-dependent manner, as perforin (purple dots) provides access to its cytoplasmic substrates.
The principal function of other (non-Asp-ase) granzymes (green and blue dots) within the target cell may
be to mimic the proinflammatory caspases that are critical for inflammasome formation and release of cy-
tokines such as IL-1b, IL-6, and TNF. It is presumed that this function of granzymes is also perforin depen-
dent but this remains to be formally demonstrated. Other intrinsic cell-death and proinflammatory pathways
can be activated by stimuli other than the granzymes, for example inflammatory stimuli operating through
Toll-like receptors (TLR), cell death through ligation of death receptors (DR), or mitochondrial perturbation.
In some situations, it might also be possible for granzymes other than B to activate target cell death, but far
less efficiently than granzyme B. Other granzyme functions (cell detachment, chemotaxis, lymphocyte
migration through the extracellular matrix) occur in the extracellular space and are independent of perforin.An Innate Path to Human B Cell Tole
Silvia Bolland1,*
1Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National I
*Correspondence: sbolland@niaid.nih.gov
DOI 10.1016/j.immuni.2008.10.001
Self-reactive B cells are eliminated during development by antibody-affi
mechanisms. Work by Isnardi et al. (2008) in this issue of Immunity sugg
from the immature B cell pool also requires innate immunity pathways.
The random nature of antibody diversifica-
tion processes guarantees that a large
number of newly generated antibodies
will recognize self-antigens. These poten-
tially harmful antibodies with self-specific-
ities are eliminated in large numbers at var-
ious steps of B cell development so that
the mature B cell repertoire of a healthy
individual is largely devoid of self-reactive
antibodies. Knowledge of this process has
greatly advanced ever since the Nussenz-
weig group developed a combination of
single-cell polymerase chain reaction
(PCR) and antibody-cloning techniques
to investigate single B cell specificities in
humans (Wardemann and Nussenzweig,
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